NCT04203316 2026-01-09
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Children's Oncology Group
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT05441514 2025-09-16
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03825796 2023-09-28
CPX-351 Plus Enasidenib for Relapsed AML
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting